[
  {
    "ts": "2026-01-14T11:55:39+00:00",
    "headline": "Update: Market Chatter: Johnson & Johnson Convinces Court to Recalculate $1 Billion Auris Award",
    "summary": "(Updates with Johnson & Johnson's response in the fourth paragraph.) Johnson & Johnson (JNJ) co",
    "url": "https://finance.yahoo.com/news/market-chatter-johnson-johnson-convinces-115539815.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c2398e86-53c0-3c8e-9602-4ca562ba48bb",
      "content": {
        "id": "c2398e86-53c0-3c8e-9602-4ca562ba48bb",
        "contentType": "STORY",
        "title": "Update: Market Chatter: Johnson & Johnson Convinces Court to Recalculate $1 Billion Auris Award",
        "description": "",
        "summary": "(Updates with Johnson & Johnson's response in the fourth paragraph.) Johnson & Johnson (JNJ) co",
        "pubDate": "2026-01-14T11:55:39Z",
        "displayTime": "2026-01-14T11:55:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-johnson-johnson-convinces-115539815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-johnson-johnson-convinces-115539815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T14:00:05+00:00",
    "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/investors-heavily-search-johnson-johnson-140005457.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "0955cdcd-c2e4-3918-a046-ded98057771a",
      "content": {
        "id": "0955cdcd-c2e4-3918-a046-ded98057771a",
        "contentType": "STORY",
        "title": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2026-01-14T14:00:05Z",
        "displayTime": "2026-01-14T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/77fQuhMZKmmejPyfoX.AMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZJQ28vQkERD4a1KYGMCgzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-johnson-johnson-140005457.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-johnson-johnson-140005457.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T15:00:04+00:00",
    "headline": "Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-reports-next-150004469.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1a822e58-8544-3f9f-b820-03e5142e20d7",
      "content": {
        "id": "1a822e58-8544-3f9f-b820-03e5142e20d7",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2026-01-14T15:00:04Z",
        "displayTime": "2026-01-14T15:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9",
          "originalWidth": 1000,
          "originalHeight": 754,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ySW4yppQRAB0XpI0aj_Aag--~B/aD03NTQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9.cf.webp",
              "width": 1000,
              "height": 754,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y7O9v2FlH8hDflZpTNqGwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-reports-next-150004469.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-reports-next-150004469.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T17:06:00+00:00",
    "headline": "Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?",
    "summary": "BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.",
    "url": "https://finance.yahoo.com/news/positive-data-camzyos-strengthen-bmys-170600610.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e2f56646-90cf-3447-b324-aca8bb6f50d9",
      "content": {
        "id": "e2f56646-90cf-3447-b324-aca8bb6f50d9",
        "contentType": "STORY",
        "title": "Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?",
        "description": "",
        "summary": "BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.",
        "pubDate": "2026-01-14T17:06:00Z",
        "displayTime": "2026-01-14T17:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/positive-data-camzyos-strengthen-bmys-170600610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/positive-data-camzyos-strengthen-bmys-170600610.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-14T21:30:00+00:00",
    "headline": "TECVAYLI速 monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide",
    "summary": "Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI速 (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide. Data confirm superior progression-free survival (PFS) and overall survival (OS",
    "url": "https://finance.yahoo.com/news/tecvayli-monotherapy-demonstrates-superior-progression-213000898.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "29a8baa0-6b45-3bed-ae41-05a020305ba4",
      "content": {
        "id": "29a8baa0-6b45-3bed-ae41-05a020305ba4",
        "contentType": "STORY",
        "title": "TECVAYLI速 monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI速 (teclistamab-cqyv) monotherapy, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death in a patient population that was predominantly refractory to anti-CD38 therapy and lenalidomide. Data confirm superior progression-free survival (PFS) and overall survival (OS",
        "pubDate": "2026-01-14T21:30:00Z",
        "displayTime": "2026-01-14T21:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "(PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qSZrWcbnRRL1JYTreG4GkQ--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k.1EfOOwAn37l11cbOcgUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tecvayli-monotherapy-demonstrates-superior-progression-213000898.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tecvayli-monotherapy-demonstrates-superior-progression-213000898.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]